Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT06217380
Other study ID # SAFE0004
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 20, 2023
Est. completion date February 15, 2024

Study information

Verified date April 2024
Source Masimo Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Clinical Trial will evaluate the Feasibility and Acceptability of Oxygen Saturation Monitoring using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date February 15, 2024
Est. primary completion date February 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for Client Participants: - Participants who are18 years of age or greater - Participants housed within a supportive housing program who intend to inject opioids - Participants who have given verbal informed consent to participate in the study Inclusion Criteria for Staff Participants: - Participant is research staff and/or Rita Thompson Residence staff - Participant is willing to give implied consent by reading and completing the staff survey Exclusion Criteria for Client Participants: - Participants deemed not suitable for the study at the discretion of the principal investigator, research staff or housing program nurses/staff - Participants with skin abnormalities at the planned application sites that may interfere with sensor application, per directions-for-use (DFU) or trans-illumination of the site, such as psoriasis, eczema, angioma, burns, scar tissue, substantial skin breakdown, nail polish, acrylic nails, infections, or other abnormalities that may interfere with MSNA functioning - Participants with known allergic reactions to foam/rubber products and/or adhesive tape Exclusion Criteria for Staff Participants: -None

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Masimo SafetyNet Alert (MSNA)
This study will explore the feasibility of implementing the Masimo SafetyNet Alert (MSNA) oxygen saturation monitoring system and the acceptance of MSNA by individuals living in a supportive housing program, who inject opioids.

Locations

Country Name City State
Canada Research Site Vanier

Sponsors (1)

Lead Sponsor Collaborator
Masimo Corporation

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of feasibility of Masimo SafetyNet Alert (MSNA) in a supportive housing program Summarizing the recruitment rate to evaluate the feasibility of Masimo SafetyNet Alert (MSNA) in a supportive housing program. 2-4 weeks
Primary Evaluation of feasibility of Masimo SafetyNet Alert (MSNA) in a supportive housing program Summarizing proportion of incomplete studies to evaluate the feasibility of Masimo SafetyNet Alert (MSNA) in a supportive housing program. 2-4 weeks
Primary Evaluation of feasibility of Masimo SafetyNet Alert (MSNA) in a supportive housing program Summarizing proportion of lost components to evaluate the feasibility of Masimo SafetyNet Alert (MSNA) in a supportive housing program. 2-4 weeks
Primary Evaluation of acceptability of Masimo SafetyNet Alert (MSNA) in a supportive housing program Summarizing the recruitment rate to evaluate the acceptability of Masimo SafetyNet Alert (MSNA) in a supportive housing program. 2-4 weeks
Primary Evaluation of acceptability of Masimo SafetyNet Alert (MSNA) in a supportive housing program Summarizing the proportion of incomplete studies to evaluate the acceptability of Masimo SafetyNet Alert (MSNA) in a supportive housing program. 2-4 weeks
Primary Evaluation of acceptability of Masimo SafetyNet Alert (MSNA) in a supportive housing program Summarizing the proportion of lost components to evaluate the acceptability of Masimo SafetyNet Alert (MSNA) in a supportive housing program. 2-4 weeks
Primary Evaluation of integration and expansion of Masimo SafetyNet Alert (MSNA) to similar housing environments Summarizing the recruitment rate to evaluate the integration and expansion of Masimo SafetyNet Alert (MSNA) to similar housing environments. 2-4 weeks
Primary Evaluation of integration and expansion of Masimo SafetyNet Alert (MSNA) to similar housing environments Summarizing the proportion of incomplete studies to evaluate the integration and expansion of Masimo SafetyNet Alert (MSNA) to similar housing environments. 2-4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04095624 - Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion N/A
Completed NCT04484610 - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study Phase 4
Recruiting NCT04598074 - Opioid Package Prototype (OPP) N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Completed NCT03570320 - Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries? N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Recruiting NCT05877157 - Pain AND Opioids After Surgery
Recruiting NCT06055205 - A Pain and Coordination Plan for Reduced Opioid Use After Accidental Injuries N/A
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Suspended NCT05001789 - Cognitive Functioning in Opioid Use Disorder N/A
Completed NCT04296396 - Opioid Prescription After Cesarean Trial Phase 3
Not yet recruiting NCT04868552 - Naloxone Education in Total Joint Patients N/A
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2
Completed NCT03472521 - Prevention of Persistent Opioid Use in Mothers Phase 4
Terminated NCT03426137 - Relieving Acute Pain (RAP) Study: A Pilot Study Phase 2